1. The diagnostic and predictive efficacy of 18F-FDG PET/CT metabolic parameters for EGFR mutation status in non-small-cell lung cancer: A meta-analysis
   Yue Guo et al, 2021, European Journal of Radiology CrossRef
2. Recent and current advances in PET/CT imaging in the field of predicting epidermal growth factor receptor mutations in non-small cell lung cancer
   Na Hu et al, 2022, Frontiers in Oncology CrossRef
3. PET Imaging-Based Phenotyping as a Predictive Biomarker of Response to Tyrosine Kinase Inhibitor Therapy in Non-small Cell Lung Cancer: Are We There Yet?
   Victor H. Gerbaudo et al, 2017, Nuclear Medicine and Molecular Imaging CrossRef
4. Non-invasive tumor genotyping using radiogenomic biomarkers, a systematic review and oncology-wide pathway analysis
   Robin W. Jansen et al, 2018, Oncotarget CrossRef
5. Association of radiomic features with epidermal growth factor receptor mutation status in non-small cell lung cancer and survival treated with tyrosine kinase inhibitors
   Changbin Wang et al, 2019, Nuclear Medicine Communications CrossRef
6. Evaluation of relationship between maximum SUV measured on 18F-FDG PET/CT with tumor pathological types, size, lymph node metastasis and distant metastasis in non-small cell lung cancer
   Sherif Mohsen Ibraheem Yousef Shalaby et al, 2022, Egyptian Journal of Radiology and Nuclear Medicine CrossRef
7. SUVmax of 18FDG PET/CT Predicts Histological Grade of Lung Adenocarcinoma
   Xiao-Yan Sun et al, 2021, Academic Radiology CrossRef
8. Can 18F-FDG PET/CT predict EGFR status in patients with non-small cell lung cancer? A systematic review and meta-analysis
   Bulin Du et al, 2021, BMJ Open CrossRef
9. Multivariate Analysis on Development of Lung Adenocarcinoma Lesion from Solitary Pulmonary Nodule
   Linxiang Yu et al, 2022, Contrast Media & Molecular Imaging CrossRef